Michael Saylor’s company’s balance sheet isn’t at imminent risk of collapse, but further capital-raising efforts could surely be hindered unless conditions improve.Markets, BTC Treasuries Theme Month, NewsRead More

You might also be interested in reading Cellectar signals NDA submission for iopofosine I-131 in WM by early 2026 amid accelerated approval focus.